Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes—Results from OASIS 1 and PIONEER PLUS Trials
Sunday, June 25, at 4:30 p.m. PT
Ballroom 20A-C
San Diego Convention Center
(Livestream Available)
Presentation: OASIS 1 Results
Filip K. Knop, MD, PhD
Professor,
Gentofte Hospital, University of Copenhagen
What is your presentation about?
In a double-blind, randomized, controlled, phase 3, superiority trial, we assessed the efficacy and safety of 68-week treatment with the once-daily oral GLP-1 analog, semaglutide 50 mg, versus placebo for overweight or obesity in adults without type 2 diabetes. Co-primary endpoints were the percentage change in body weight and the achievement of weight reduction of at least 5% at week 68 for oral semaglutide 50 mg versus placebo, assessed regardless of treatment discontinuation or use of other weight-lowering therapies. Safety was assessed in participants who received at least one dose of trial drug.
What makes this topic important in 2023?
In people with overweight or obesity, reducing body weight is known to reduce the risk of weight-related complications such as type 2 diabetes. Semaglutide is a GLP-1 analog available as subcutaneous and oral formulations, but efficacy and safety of oral doses relevant for the treatment of overweight or obesity in individuals without diabetes remain uncertain.
How did you become involved with this area of diabetes research or care?
I have been involved in diabetes and metabolic research since my fellowship at University of Texas, Southwestern Medical Center in Dallas in 1999/2000 where I was supervised by Professor Christopher B. Newgard. Currently, my research focuses on human metabolism, regulation of appetite and food intake, and the pathophysiology of obesity and related disorders, including type 2 diabetes and non-alcoholic fatty liver disease.
How do you think your presentation will impact diabetes research or care?
The data that I will present on behalf of the OASIS 1 investigators are the first to describe the weight-lowering effect and safety of an oral GLP-1 analog (once-daily semaglutide 50 mg) in adults with overweight or obesity, without type 2 diabetes, and may, thus, guide the future treatment of obesity.
What are you most looking forward to at the 83rd Scientific Sessions?
I am looking forward to discussing new research and clinical trial results with good colleagues from around the globe. I also look forward to seeing my younger colleagues from the Center for Clinical Metabolic Research at Gentofte Hospital, University of Copenhagen, presenting their exciting results at the meeting.